The secure way to view our annual materials and to vote.
Our report on activities & financial performance throughout the year.
Details about our annual meeting & matters to be voted upon.
Vote your proxy online now or by phone by dialing 866-859-1992.
DATE: June 17, 2024
TIME: 1:00 p.m. Pacific Time
You must register to participate in the meeting. Please register below.
Deadline to register is June 14, 2024, 8:00 p.m. Pacific Time.
Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell therapies and genetic medicines with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes investigational allogeneic CAR-T cell therapies for both solid tumors and hematologic cancers as well as investigational in vivo genetic medicines that address patient populations with high unmet medical need. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. The Company has formed a global strategic collaboration with Roche to unlock the promise of cell therapies for patients with hematologic malignancies.
Copyright © BetaNXT, Inc. or its affiliates.
All Rights Reserved.